Impaired recovery of Epstein-Barr virus (EBV)--specific CD8+ T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative disease.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Blood

• Publication date

  2003-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1182/BLOOD-2002-10-3001PMID 12576337
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phenotypic analysis of antigen-specific T lymphocytes. Science. 1996. 274: 94-96.

  2011cited by this paper
• T-Lymphocyte Reconstitution in Recipients of Bone Marrow Transplants With and Without GVHD : Imbalances of T-Cell Subpopulations Having Unique Regulatory and Cognitive Functions

  2005cited by this paper
• The dispersal of mucosal memory B cells: evidence from persistent EBV infection.

  2002cited by this paper
• HLA tetramers and anti-CMV immune responses: from epitope to immunotherapy.

  2002cited by this paper
• Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas.

  2002cited by this paper
• Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation.

  2002cited by this paper
• Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease1

  2002cited by this paper
• Epitope-specific Evolution of Human CD8+ T Cell Responses from Primary to Persistent Phases of Epstein-Barr Virus Infection

  2002cited by this paper
• Molecular quantification of viral load in plasma allows for fast and accurate prediction of response to therapy of Epstein–Barr virus‐associated lymphoproliferative disease after allogeneic stem cell transplantation

  2001cited by this paper
• Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell--depleted SCT.

  2001cited by this paper
• Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation.

  2001cited by this paper
• Tetramer-based quantification of cytomegalovirus (CMV)-specific CD8+ T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection.

  2001cited by this paper
• Dysfunctional Epstein-Barr virus (EBV)-specific CD8(+) T lymphocytes and increased EBV load in HIV-1 infected individuals progressing to AIDS-related non-Hodgkin lymphoma.

  2001cited by this paper
• Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients.

  2001cited by this paper
• Development of a Real-Time Quantitative Assay for Detection of Epstein-Barr Virus

  2000cited by this paper
• A global appraisal of immunodominant CD8 T cell responses to Epstein‐Barr virus and cytomegalovirus by bulk screening

  2000cited by this paper
• Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells.

  2000cited by this paper
• The Importance of Exogenous Antigen in Priming the Human CD8+ T Cell Response: Lessons from the EBV Nuclear Antigen EBNA11

  2000cited by this paper
• Rapid reconstitution of Epstein-Barr virus-specific T lymphocytes following allogeneic stem cell transplantation.

  2000cited by this paper
• Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study.

  1999cited by this paper
• B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcome

  1999cited by this paper
• A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers.

  1999cited by this paper
• Frequency of CD8(+) T lymphocytes specific for lytic and latent antigens of Epstein-Barr virus in healthy virus carriers.

  1999cited by this paper
• Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection.

  1998cited by this paper
• Lymphoproliferative disorders following allogeneic bone marrow transplantation: the Vancouver experience

  1998cited by this paper
• Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients.

  1998cited by this paper
• Evaluation of a method for counting absolute numbers of cells with a flow cytometer

  1997cited by this paper
• Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection.

  1997cited by this paper
• Progressive loss of CD8+ T cell-mediated control of a gamma-herpesvirus in the absence of CD4+ T cells

  1996cited by this paper
• Phenotypic Analysis of Antigen-Specific T Lymphocytes

  1996cited by this paper
• The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL

  1996cited by this paper
• Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders.

  1995cited by this paper
• Early identification of Epstein‐Barr virus‐associated post‐transplantation lymphoproliferative disease

  1995cited by this paper
• Detection of multiple Epstein‐Barr viral strains in allogeneic bone marrow transplant recipients

  1992cited by this paper
• Reconstruction of the haemopoietic and immune systems after marrow transplantation.

  1990cited by this paper
• CD3+, 4+ and/or 8+ T cells and CD3+, 4-, 8- T cells repopulate at different rates after allogeneic bone marrow transplantation.

  1989cited by this paper
• Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia.

  1989cited by this paper
• Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation.

  1988cited by this paper
• T-lymphocyte reconstitution in recipients of bone marrow transplants with and without GVHD: imbalances of T-cell subpopulations having unique regulatory and cognitive functions.

  1982cited by this paper

• Coinfection of EBV with other pathogens: a narrative review

  2024cites this paper
• Tabelecleucel for EBV+ PTLD after allogeneic HCT or SOT in a multicenter expanded access protocol

  2024cites this paper
• Mechanistic Understanding of EBV+Lymphoproliferative Disease Development After Transplantation

  2024cites this paper
• Early T-cell reconstitution predicts risk of EBV reactivation after allogeneic hematopoietic stem cell transplantation

  2024cites this paper
• In vitro and In vivo evidence that the switch from calcineurin to mTOR-inhibitors may be a strategy for immunosuppression in Epstein-Barr-Virus-associated post-transplant lymphoproliferative disorder.

  2022cites this paper
• Reconstitution of EBV-directed T cell immunity by adoptive transfer of peptide-stimulated T cells in a patient after allogeneic stem cell transplantation for AITL

  2022cites this paper
• Donor activating killer cell immunoglobulin‐like receptors genes correlated with Epstein–Barr virus reactivation after haploidentical haematopoietic stem cell transplantation

  2021cites this paper
• Predictive factors for vaccine failure to guide vaccination in allogeneic hematopoietic stem cell transplant recipients

  2021cites this paper
• Proteomic approaches to investigate gammaherpesvirus biology and associated tumorigenesis.

  2021cites this paper
• Reconstitution of T cell immunity against EBV in the immunocompromised host by adoptive transfer of peptide-stimulated T cells after allogeneic stem cell transplantation

  2021cites this paper
• Transplantation for congenital heart disease is associated with an increased risk of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in children.

  2021cites this paper
• Management of PTLD After Hematopoietic Stem Cell Transplantation: Immunological Perspectives

  2020cites this paper
• Cytomegalovirus and Epstein-Barr Infections: Prevalence and Impact on Patients with Hematological Diseases

  2020cites this paper
• Epstein-Barr Virus and Monoclonal Gammopathy of Clinical Significance in Autologous Stem Cell Transplantation for Multiple Sclerosis.

  2019cites this paper
• Lymphocyte subset at time of Epstein‐Barr viremia post‐allogeneic hematopoietic stem cell transplantation in children may predict development of post‐transplant lymphoproliferative disease: CD8:CD20 ratio as a sensitive predictor

  2019cites this paper
• Epstein-Barr Virus Infection and Posttransplant Lymphoproliferative Disease

  2019cites this paper
• Medical Course and Complications After Hematopoietic Cell Transplantation

  2018cites this paper
• The kinetics of torque teno virus plasma DNA load shortly after engraftment predicts the risk of high-level CMV DNAemia in allogeneic hematopoietic stem cell transplant recipients

  2018cites this paper
• [Past and present of monitoring the functional immune response developed against Epstein-Barr and Adenovirus in hematopoietic stem cell transplantation].

  2018cites this paper
• Treatment of Epstein–Barr virus associated central nervous system diseases after allogeneic hematopoietic stem cell transplantation with intrathecal donor lymphocyte infusion

  2018cites this paper
• Inverse correlation of Vδ2+ T‐cell recovery with EBV reactivation after haematopoietic stem cell transplantation

  2018cites this paper
• Post‐transplant lymphoproliferative disorders

  2017cites this paper
• Cancer After Kidney Transplantation

  2017cites this paper
• Association of Epstein–Barr virus reactivation with the recovery of CD4/CD8 double-negative T lymphocytes after haploidentical hematopoietic stem cell transplantation

  2017cites this paper
• Successful management of EBV-PTLD in allogeneic bone marrow transplant recipient by virological-immunological monitoring of EBV infection, prompt diagnosis and early treatment.

  2016cites this paper
• Epstein–Barr Virus Infection and Lymphoproliferative Disorders After Transplantation

  2016cites this paper
• Rapid reconstitution of CD4 T cells and NK cells protects against CMV-reactivation after allogeneic stem cell transplantation

  2016cites this paper
• Post-transplant lymphoproliferative disorders

  2016cites this paper
• Epstein-Barr Virus-Related Post-Transplantation Lymphoproliferative Disorder after Unmanipulated Human Leukocyte Antigen Haploidentical Hematopoietic Stem Cell Transplantation: Incidence, Risk Factors, Treatment, and Clinical Outcomes.

  2015cites this paper
• Memory B-cell reconstitution following allogeneic hematopoietic stem cell transplantation is an EBV-associated transformation event.

  2015cites this paper
• How I Treat How I treat posttransplant lymphoproliferative disorders

  2015cites this paper
• Epstein-Barr Virus Reactivation does not Impact Total T-Cell Reconstitution but is associated with Decreased Functional T Cells after Stem Cell Transplantation

  2015cites this paper
• The immunology of Epstein-Barr virus-induced disease.

  2015influential citation
• How we diagnose and treat posttransplant lymphoproliferative disorders

  2015cites this paper
• How I treat posttransplant lymphoproliferative disorders.

  2015cites this paper
• Posttransplant lymphoproliferative disorders following liver transplantation: Where are we now?

  2015cites this paper
• Features of Epstein-Barr virus reactivation after allogeneic hematopoietic cell transplantation in Korean children living in an area of high seroprevalence against Epstein-Barr virus

  2014cites this paper
• EBV-associated post-transplant lymphoproliferative disorder following in vivo T-cell-depleted allogeneic transplantation: clinical features, viral load correlates and prognostic factors in the rituximab era

  2014cites this paper
• Malignancies associated with epstein-barr virus: pathobiology, clinical features, and evolving treatments.

  2014cites this paper
• Manifestations of fulminant CD8 T-cell post-transplant lymphoproliferative disorder following the administration of rituximab for lymphadenopathy with a high level of Epstein-Barr Virus (EBV) replication after allogeneic hematopoietic stem cell transplantation.

  2014cites this paper
• Hepatitis E virus: an underestimated opportunistic pathogen in recipients of allogeneic hematopoietic stem cell transplantation.

  2013cites this paper
• Determining EBV load: current best practice and future requirements

  2013cites this paper
• Lymphknotenpathologie – ein Update

  2013cites this paper
• Adoptive transfer of epstein-barr virus (EBV) nuclear antigen 1-specific t cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation.

  2013cites this paper
• Increased proportion of perforin-expressing CD8+T-cells indicates control of herpesvirus reactivation in children after stem cell transplantation.

  2013cites this paper
• Therapeutic drug monitoring: a way to improve long-term immunological balance?

  2013cites this paper
• Adoptive T-cell Transfer for Refractory Viral Infections with Cytomegalovirus, Epstein-Barr Virus or Adenovirus after Allogeneic Stem Cell Transplantation

  2013cites this paper
• Adoptive T-cell immunotherapy from third-party donors: characterization of donors and set up of a T-cell donor registry

  2013cites this paper
• Epstein–Barr Virus Infection and Posttransplant Lymphoproliferative Disorder

  2013cites this paper
• Immune reconstitution after anti-thymocyte globulin-conditioned hematopoietic cell transplantation.

  2012cites this paper
• Adequate control of primary EBV infection and subsequent reactivations after cardiac transplantation in an EBV seronegative patient.

  2012cites this paper
• T-cell therapy in the treatment of post-transplant lymphoproliferative disease

  2012cites this paper
• Ex Vivo Alloanergization with Belatacept: A Strategy to Selectively Modulate Alloresponses after Transplantation

  2012cites this paper
• The EBV-HIV interrelationship and the value of EBV-DNA analysis

  2012cites this paper
• How I treat HHV8/KSHV-related diseases in posttransplant patients.

  2012cites this paper
• Effective control of Epstein–Barr virus infection following pediatric liver transplantation by monitoring of viral DNA load and lymphocyte surface markers

  2012cites this paper
• First analysis of human herpesvirus 6T-cell responses: specific boosting after HHV6 reactivation in stem cell transplantation recipients.

  2012cites this paper
• 4 Posttransplant Lymphoproliferative Disorders Following Kidney Transplantation

  2012cites this paper
• Long-term outcome for immune suppression and immune related lymphoproliferative disorder: prospective data from the United Kingdom Children's Leukaemia and Cancer Group registry 1994–2004

  2012cites this paper
• Evaluation of the role of Epstein-Barr virus and cellular gene expression in paediatric and adult transplant recipients

  2012cites this paper
• Posttransplant Lymphoproliferative Disorders Following Kidney Transplantation

  2011cites this paper
• Pre‐emptive rituximab based on viraemia and T cell reconstitution: a highly effective strategy for the prevention of Epstein–Barr virus‐associated lymphoproliferative disease following stem cell transplantation

  2011cites this paper
• BK polyomavirus infection and nephropathy: the virus–immune system interplay

  2011cites this paper
• Insufficient recovery of thymopoiesis predicts for opportunistic infections in allogeneic hematopoietic stem cell transplant recipients

  2011cites this paper
• Epstein-Barr virus-driven lymphoproliferative disorder post-CAMPATH-1H (alemtuzumab) in refractory polymyositis.

  2011cites this paper
• Epstein-Barr Virus*

  2011cites this paper
• Strategies to prevent EBV reactivation and posttransplant lymphoproliferative disorders (PTLD) after allogeneic stem cell transplantation in high-risk patients.

  2011influential citation
• Isolated cerebral manifestation of Epstein–Barr virus‐associated post‐transplant lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation: a case of clinical and diagnostic challenges

  2011cites this paper
• The clinical value of concomitant Epstein Barr virus (EBV)-DNA load and specific immune reconstitution monitoring after allogeneic hematopoietic stem cell transplantation.

  2011cites this paper
• High incidence of post transplant lymphoproliferative disorder after antithymocyte globulin-based conditioning and ineffective prediction by day 28 EBV-specific T lymphocyte counts

  2011cites this paper
• Simultaneous Isolation of CD8+ and CD4+ T Cells Specific for Multiple Viruses for Broad Antiviral Immune Reconstitution After Allogeneic Stem Cell Transplantation

  2011cites this paper
• Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells.

  2010cites this paper
• Reconstitution immunitaire et immunothérapie adoptive anti-virales après allogreffe de cellules souches hématopoiétiques

  2010cites this paper
• Hematopoietic Stem Cell Transplantation after Posttransplant Lymphoproliferative Disorder

  2010cites this paper
• Using Epstein-Barr Viral Load Assays To Diagnose, Monitor, and Prevent Posttransplant Lymphoproliferative Disorder

  2010cites this paper
• High level of perforin expression in T cells: An early prognostic marker of the severity of herpesvirus reactivation after allogeneic stem cell transplantation in adults.

  2010cites this paper
• The impact of CD4+Foxp3+ Treg on immunity to murine cytomegalovirus after bone marrow transplantation depends on the peripheral or thymic source of T cell regeneration.

  2010cites this paper
• Immunotherapeutic options for Epstein-Barr virus-associated lymphoproliferative disease following transplantation.

  2010cites this paper
• Infektionen und Immuntherapie

  2010cites this paper
• Immunologic and virologic analyses in pediatric liver transplant recipients with chronic high Epstein-Barr virus loads.

  2010cites this paper
• Incidence and Dynamics of Epstein-Barr Virus Reactivation After Alemtuzumab-Based Conditioning for Allogeneic Hematopoietic Stem-Cell Transplantation

  2010cites this paper
• Epstein-Barr virus infections after allogeneic stem cell transplantation: a comparison between non-malignant and malignant hematological disorders

  2010cites this paper
• EBV viral load detection in clinical virology.

  2010cites this paper
• Transplantation Immunology: Aspects of allo- and EBV-specific reactivity

  2010cites this paper
• Posttransplant Lymphoproliferative Disease (PTLD) in Hematopoietic Stem Cell Transplantation (HSCT)

  2010cites this paper
• Molecular Targeting of Post-transplant Lymphoproliferative Disorders

  2010cites this paper
• Update on EBV monitoring, detection and therapy in PTLD after solid organ transplant

  2010cites this paper
• Regulatory T cells and immune tolerance after allogeneic hematopoietic stem cell transplantation

  2010cites this paper
• Epstein—Barr Viral Load Testing: Role in the Prevention, Diagnosis and Management of Posttransplant Lymphoproliferative Disorders

  2010cites this paper
• Generation of calcineurin inhibitor resistant EBV-CTLs for the treatment of post transplant lymphoma

  2010cites this paper
• How I treat EBV lymphoproliferation.

  2009cites this paper
• Management of infections complicating allogeneic hematopoietic stem cell transplantation.

  2009cites this paper
• Delay in B-lymphocyte recovery and function following rituximab for EBV-associated lymphoproliferative disease early post-allogeneic hematopoietic SCT

  2009cites this paper
• The effects of acute malaria on Epstein-Barr virus (EBV) load and EBV-specific T cell immunity in Gambian children.

  2009cites this paper
• Lymphocyte markers and prediction of long-term renal allograft acceptance

  2009cites this paper
• Immune surveillance of EBV-infected B cells and the development of non-Hodgkin lymphomas in immunocompromised patients

  2008cites this paper
• Monitoring of Epstein‐Barr virus load after hematopoietic stem cell transplantation for early intervention in post‐transplant lymphoproliferative disease

  2008cites this paper
• CD4 and CD8 T cell responses to tumour-associated Epstein–Barr virus antigens in nasopharyngeal carcinoma patients

  2008cites this paper
• EBV Lymphoproliferative Disease After Transplantation

  2008cites this paper
• Immunological reconstitution after hematopoietic cell transplantation – its relation to the contents of the graft

  2008cites this paper